Abstract:When SARS‐CoV‐2 enters inside the cell by fusion process it encodes few proteins including main protease with the help of cellular ribosomes. This main protease mediates the maturation cleavage of polyproteins at 11 different regions, which is a notable step in virus's life cycle. SARS‐CoV‐2 Mpro is mainly a homo‐dimeric enzyme consisting of three domains. The large substrate‐binding site with a catalytic dyad of His41 and Cys145 is located between chymotrypsin‐like domains I and picornavirus 3C protease‐like domain II. Inhibition of this substrate binding site disrupt the replication process. But being large substrate‐binding site, peptide is more suitable than small molecules for inhibiting this crucial site. The outcome of this computational study displays that the attachment of peptide with Mpro protease can be a good strategy to inhibit the substrate‐binding site which may lead to disruption of replication process of SARS CoV‐2. The COVID‐19 pandemic has been a public health emergency, with deadly forms constantly emerging around the world, highlighting the dire need for highly effective antiviral therapeutics. Peptide therapeutics show significant potential for this viral disease due to their efficiency, safety, and specificity. Here, two thousand seven hundred eight antibacterial peptides were screened computationally targeting the Main protease (Mpro) of SARS CoV‐2. Six top‐ranked peptides according to their binding scores, binding pose were investigated by molecular dynamics to explore the interaction and binding behavior of peptide‐Mpro complexes. The structural and energetic characteristics of Mpro‐DRAMP01760 and Mpro‐DRAMP01808 complexes fluctuated less during a 250 ns MD simulation. In addition, three peptides (DRAMP01760, DRAMP01808, and DRAMP01342) bind strongly to Mpro protein, according to the free energy landscape and principal component analysis. Peptide helicity and secondary structure analysis are in agreement with our findings. Interaction analysis of protein‐peptide complexes demonstrated that Mpro's residue CYS145, HIS41, PRO168, GLU166, GLN189, ASN142, MET49, and THR26 play significant contributions in peptide‐protein attachment. Binding free energy analysis (MM‐PBSA) demonstrated the energy profile of interacting residues of Mpro in peptide‐Mpro complexes. To summarize, the peptides DRAMP01808 and DRAMP01760 may be highly Mpro specific, resulting disruption in a viral replication and transcription. The results of this research are expected to assist future research toward the development of antiviral peptide‐based therapeutics for Covid‐19 treatment.

Bioengineered amyloid peptide for rapid screening of inhibitors against main protease of SARS-CoV-2

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Structure-based Virtual Screening, in Silico Docking, ADME Properties Prediction and Molecular Dynamics Studies for the Identification of Potential Inhibitors Against SARS-CoV-2 Mpro.

Molecular Modelling, Synthesis, and In-Vitro Assay to Identify Potential Antiviral Peptides Targeting the 3-Chymotrypsin-Like Protease of SARS-CoV-2

Large scale peptide screening against main protease of SARS CoV‐2

High-throughput Screening of SARS-CoV-2 Main and Papain-Like Protease Inhibitors

An Enhanced Hybrid Screening Approach to Identify Potent Inhibitors for the SARS-CoV-2 Main Protease From the NCI Compound Library

Improved fluorescence‐based assay for rapid screening and evaluation of SARS‐CoV‐2 main protease inhibitors

Biochemical screening for SARS-CoV-2 main protease inhibitors

Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay

Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2

Computer-aided drug design for virtual-screening and active-predicting of main protease (Mpro) inhibitors against SARS-CoV-2

In silico screening of potential inhibitors from Cordyceps species against SARS-CoV-2 main protease

Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M<SUP>pro</SUP>

Discovery of Inhibitors Against SARS-CoV-2 Main Protease Using Fragment-Based Drug Design

A Quick Route to Multiple Highly Potent SARS‐CoV‐2 Main Protease Inhibitors**

High-throughput Screening and Experimental Identification of Potent Drugs Targeting SARS-CoV-2 Main Protease

Miniaturized Modular Click Chemistry‐enabled Rapid Discovery of Unique SARS‐CoV‐2 Mpro Inhibitors With Robust Potency and Drug‐like Profile

A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors

Chemical Proteomics Approaches for Screening Small Molecule Inhibitors Covalently Binding to SARS-Cov-2

Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and its Variants Displaying Potent Antiviral Activity